New PET probe aims to spot lung scarring earlier

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * No gender restriction, age ≥18 years (inclusive); * Patients with interstitial lung disease who meet one of the following diagnoses: connective tissue disease-associated interstitial lung disease (CTD-ILD), idiopathic nonspecific interstitial pneumonia (iNSIP), chronic allergic pneumonia, sarcoidosis, environmental/occupational lung disease, or unclassifiable idiopathic interstitial disease (IIP); * Screening subjects who were definitively diagnosed with interstitial lung disease (ILD) by high-resolution computed tomography (HRCT) within the preceding 6 months; * In the first 3 months prior to screening, the carbon monoxide diffusion capacity (DLCO) (Hb-corrected) was within 30% to 80% (inclusive) of the predicted value; the forced vital capacity (FVC) was within 40% to 70% (inclusive) of the predicted value; * The chief complaint is memory decline or other symptoms of cognitive impairment, with a disease course of ≥3 months; * meets the diagnostic criteria for cognitive impairment caused by Alzheimer's disease (AD), mild cognitive impairment (MCI), or other related neurodegenerative diseases; * The scores on the cognitive function screening scale meet the criteria for cognitive impairment (e.g., Mini-Mental State Examination (MMSE) \<24 points, or Montreal Cognitive Assessment (MoCA) \<26 points); * Exclusion of cognitive dysfunction caused by severe depression, brain trauma, brain tumors, cerebrovascular accidents, etc. Exclusion Criteria: * patients in critical condition requiring emergency care; * Individuals with drug and/or alcohol abuse, or those with allergic predisposition; * women of childbearing potential, pregnant and lactating women; * bacterial, viral or fungal infections that require systemic treatment; * The study excluded participants deemed unsuitable by the investigators.